Clinical trials: Influenza, completed
Influenza
Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza
This study will evaluate the safety, pharmacokinetics and effectiveness of a single dose of 600 mg IV peramivir in the treatment of elderly subjects with acute uncomplicated influenza infection and in subjects with acute…
- Trial name
- NCT02635724
- Testing
- Peramivir
- Where
- 15 sites in United States
- Volunteers
- 74 people
- Sponsor
- BioCryst Pharmaceuticals
Influenza
Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model
A Phase 2, single center, randomized, double blind study evaluating the safety, efficacy, and immunogenicity of MVA NP+M1 in the H3N2 human influenza challenge model; on healthy adult volunteers.
- Trial name
- NCT03883113
- Testing
- MVA-NP+M1, Saline, H3N2 (A/Belgium/2417/2015)
- Where
- Belgium
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Barinthus Biotherapeutics
Asthma in Children, Vaccine Adverse Reaction
Safety of LAIV4 in Children With Asthma
This is a prospective randomized, open label clinical trial in approximately 300 children aged 5-11 years with a physician diagnosis of persistent asthma.
- Conditions
- Asthma in Children, Vaccine Adverse Reaction, Vaccine Reaction, Asthma
- Trial name
- NCT03600428
- Testing
- Live Attenuated Influenza Vaccine (LAIV), Inactivated Influenza Vaccine (IIV)
- Where
- 3 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Influenza
Procalcitonin Role in Influenza Patients With Regard to Morbidity, Mortality and Antibiotic Use
The investigators intend to observe the inflammatory marker procalcitonin (PCT) in comparison with patient variables on morbidity, mortality and antibiotic treatment.
- Trial name
- NCT04171128
- Testing
- antibiotic stewardship efforts
- Where
- 2 sites in Norway
- Volunteers
- 119 people
- Sponsor
- Ostfold Hospital Trust
Human Influenza
Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents
Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection (trivalent, seasonal influenza vaccine, active ingredient content: 6 μg HA/strain/0.5 ml) for Children and Adolescents.
- Trial name
- NCT02387294
- Testing
- Vaccination with Fluval AB Novo suspension for injection, half dose of a single intramuscular dose (0.25 ml), Vaccination with Fluval AB Novo suspension for injection, single intramuscular dose (0.5 ml)
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Seasonal Influenza
Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects
Influenza poses a significant threat to individual and public health, and influenza vaccination with a trivalent inactivated influenza vaccine is widely recommended to children, adults at risks and elderly.
- Trial name
- NCT01161264
- Testing
- Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011
- Where
- Germany
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Human Influenza
Safety of 4Fluart ID Suspension for Injection in Adult Subjects
The primary objective of the study is to evaluate the safe usability of the study drugs, i.e. 4Fluart ID 1 µg haemagglutinin (HA)/0.1 ml QIV and 4Fluart ID 2 µg haemagglutinin (HA)/0.1 ml QIV in terms of safety concerns emerged.
- Trial name
- NCT03448705
- Testing
- 4Fluart ID suspension for injection study drug 1 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted), 4Fluart ID suspension for injection study drug 2 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted), 3Fluart suspension for injection, influenza vaccine (whole virion, inactivated, adjuvanted)
- Where
- Hungary
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Influenza
Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age
The purpose of this study is to characterize the safety and efficacy of GSK Biologicals' H1N1 flu candidate vaccines GSK2340274A and GSK2340273A in children 6 months to less than 10 years of age.
- Trial name
- NCT01051661
- Testing
- GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations), GSK Biologicals' investigational vaccine GSK2340273A (alternative formulations)
- Where
- 17 sites in Australia, Brazil and 6 more
- Volunteers
- 6,154 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Vaccine
Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine
The clinical study will evaluate safety and the immune response of a prime- boost regimen with a live attenuated influenza vaccine (LAIV) prime and an inactivated split influenza vaccine (IIV) boost with or without adjuvant.
- Trial name
- NCT03300050
- Testing
- cH8/1N1 LAIV, AS03-adjuvanted cH5/1N1 IIV, cH5/1N1 IIV
- Where
- 2 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- PATH
Influenza
Comparison of Full-dose Flu Vaccine to Half-dose Flu Vaccine
This study compared full-dose Flu vaccine to half-dose Flu-vaccine during the 2004-2005 flu season.
- Trial name
- NCT00283283
- Testing
- Fluzone® (Aventis Pasteur inactivated influenza vaccine)
- Where
- 2 sites in United States
- Volunteers
- 1,316 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Influenza, Otitis Media
Evaluation of Moderate to Severe Influenza Outcomes in Children
The purpose of this study was to determine whether moderate-severe endpoints (including high fever, lower respiratory tract disease, acute otitis media, or serious extra-pulmonary complications) were predictive of…
- Conditions
- Influenza, Otitis Media, Lower Resp Tract Infection, Encephalitic Infection
- Trial name
- M2SFlu (NCT02979626)
- Testing
- Respiratory nasal swab
- Where
- 2 sites in United States
- Volunteers
- 1,478 people
- Sponsor
- University of Colorado, Denver
Cold, Cold Symptom
Ability of Beta-glucan Supplementation to Augment Immune Function
This proposed study is designed to assess the efficacy of a capsule containing beta-glucan taken orally daily as compared to a placebo capsule on the URTI symptoms, and the immune response change in marathon runners
- Conditions
- Cold, Cold Symptom, Flu, Flu Symptom
- Trial name
- NCT03769012
- Testing
- Beta-Glucan
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Kemin Foods LC
Influenza, Human
Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy
This research aims to identify which behavioral science strategies are most effective at increasing flu vaccination rates overall and based on patients' individual characteristics.
- Trial name
- NCT04590066
- Testing
- Flu shot text messages
- Where
- United States
- Volunteers
- 734,383 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Influenza
Evaluation the Safety and Tolerance of GP681 Tablets in Healthy Subjects
Influenza (influenza for short) is an acute respiratory infectious disease caused by influenza virus. The symptoms of the disease range from mild, moderate to severe, and severe cases require hospitalization and may die.
- Trial name
- NCT04729764
- Testing
- GP681 Tablet
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Influenza, Human
Evaluating The Safety And Clinical Efficacy Of Elderberry Extract In Patients With Influenza
This research is being done to determine if an extract of cooked elderberries will help decrease the duration and severity of influenza symptoms in patients with confirmed influenza.
- Trial name
- NCT03410862
- Testing
- Elderberry Extract
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- michael macknin
Influenza
Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects
This clinical study will assess the safety, tolerability and immunogenicity of VAL-339851 in healthy subjects.
- Trial name
- NCT03345043
- Testing
- VAL-339851
- Where
- United States
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza
Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza
This study will evaluate the efficacy, safety, and pharmacokinetics of baloxavir marboxil in combination with a standard-of-care (SOC) neuraminidase inhibitor (NAI) (i.e., oseltamivir, zanamivir, or peramivir) compared with a…
- Trial name
- NCT03684044
- Testing
- Baloxavir Marboxil
- Where
- 170 sites in United States, Argentina and 26 more
- Volunteers
- 363 people
- Sponsor
- Hoffmann-La Roche
Intubation Complication, Intubation; Difficult or Failed
Prehospital Intubation of COVID-19 Patient With Personal Protective Equipment
The safety and efficacy of a laryngoscopy as a primary intubation tool in urgent endotracheal intubation of cardiac arrest patients with suspected/confirmed COVID-19 has not been well-described in the literature.
- Conditions
- Intubation Complication, Intubation; Difficult or Failed, Cardiac Arrest, Influenza
- Trial name
- NCT04365608
- Testing
- Direct laryngoscopy, Vie Scope laryngoscopy
- Where
- 2 sites in Poland
- Volunteers
- 90 people
- Sponsor
- Lazarski University
Influenza, Organ Transplantation
Reducing the Burden of Influenza After Solid-Organ Transplantation
Influenza is associated with significant morbidity and mortality in solid-organ transplant (SOT) recipients and it is mainly prevented by seasonal influenza vaccination.
- Trial name
- STOP-FLU (NCT03699839)
- Testing
- High-dose influenza vaccine, MF59-adjuvanted influenza vaccine, Standard intramuscular influenza vaccine
- Where
- 9 sites in Spain, Switzerland
- Volunteers
- 619 people
- Sponsor
- Oriol Manuel
Influenza A
Study to Assess Safety, Tolerability and Reactogenicity of Vaccine "UniFluVec" After Two Intranasal Administrations in Healthy Volunteers
A double-blind, randomized, placebo-controlled, Phase I clinical study of the safety, tolerability, reactogenicity and immunogenic activity of the universal influenza vector vaccine "UniFluVec" at two dose levels after two…
- Trial name
- NCT04650971
- Testing
- UniFluVec
- Where
- Russia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Pharmenterprises Biotech LLC